The overarching mission of the Hanns A. Pielenz Clinical Research Center for Myeloproliferative Neoplasms (HAP-CRC-MPN) is to develop a comprehensive approach to understanding the biology of myeloproliferative neoplasms (MPNs), leading to the development of new and effective therapies through translational and clinical research.
The main objectives of the HAP-CRC-MPN are to identify and develop treatment strategies to effectively treat MPNs, prolong patients’ lives and ultimately cure them. Our efforts are focused in three key areas:
- Conduct clinical trials with novel agents developed specifically for patients with MPNs. The center will provide the clinical infrastructure allowing for the conduct of prime clinical research in MPNs.
Tissue Bank/Laboratory Research
- Establish a centralized tissue bank for collection of patient samples for translational research and a database for clinical and pathology information.
- Disseminate information about MPNs and educate patients, families, and healthcare providers about the latest MPN treatments and research strategies.